Octapharma Biopharmaceuticals GmbH – we know the score
Expertise, experience and commitment are the basis for excellent work and perfect results. Since the founding of Octapharma Biopharmaceuticals GmbH in 1997, our experience in the area of research and development in the field of human cell lines has evolved extensively, resulting in the maturation of an effective, product-oriented biotechnology firm.
Our core competence is the development of recombinant pharmaceuticals as a modern alternative to plasma products.
The demand for recombinant therapies is steadily increasing. The proof from market statistics is quite impressive: from 2002 to 2005, the market share for recombinant proteins in 25 research companies rose by approximately 8% overall. The example of the Factor VIII product, which is derived from plasma, demonstrates this exceptionally clear-the shift of plasma-derived Factor VIII to recombinant Factor VIII was reflected in a turnover share increase and rapid growth of 96%.
Our work confirms these trend-setting and innovative discoveries, which undoubtly makes clear that Octapharma Biopharmaceuticals GmbH is on the right path.
“The use of human cells as an innovation?”
A serious complication in the management of hemophilia is the formation of antibodies, which significantly hinders the treatment process. Octapharma is one of the first companies investigating the use of a human cell line for production of therapeutic coagulation proteins, with the goal that the manufactured pharmaceutical products are as close as possible to those produced physiologically in plasma, in regards to structure, efficacy and tolerability. We hope that this approach can reduce the formation of problematic antibodies.